Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Introduction: Although acute transverse myelitis (ATM) is a rare neurological condition (1.34-4.6 cases per million/year) COVID-19-associated ATM cases have occurred during the pandemic. Case-finding methods: We report a patient from Panama with SARS-CoV-2 infection complicated by ATM and present a comprehensive clinical review of 43 patients with COVID-19-associated ATM from 21 countries published from March 2020 to January 2021. In addition, 3 cases of ATM were reported as serious adverse events during the clinical trials of the COVID-19 vaccine ChAdOx1 nCoV-19 (AZD1222). Results: All patients had typical features of ATM with acute onset of paralysis, sensory level and sphincter deficits due to spinal cord lesions demonstrated by imaging. There were 23 males (53%) and 20 females (47%) ranging from ages 21- to 73- years-old (mean age, 49 years), with two peaks at 29 and 58 years, excluding 3 pediatric cases. The main clinical manifestations were quadriplegia (58%) and paraplegia (42%). MRI reports were available in 40 patients; localized ATM lesions affected ≤3 cord segments (12 cases, 30%) at cervical (5 cases) and thoracic cord levels (7 cases); 28 cases (70%) had longitudinally-extensive ATM (LEATM) involving ≥4 spinal cord segments (cervicothoracic in 18 cases and thoracolumbar-sacral in 10 patients). Acute disseminated encephalomyelitis (ADEM) occurred in 8 patients, mainly women (67%) ranging from 27- to 64-years-old. Three ATM patients also had blindness from myeloneuritis optica (MNO) and two more also had acute motor axonal neuropathy (AMAN). Conclusions: We found ATM to be an unexpectedly frequent neurological complication of COVID-19. Most cases (68%) had a latency of 10 days to 6 weeks that may indicate post-infectious neurological complications mediated by the host’s response to the virus. In 32% a brief latency (15 hours to 5 days) suggested a direct neurotropic effect of SARS-CoV-2. The occurrence of 3 reported ATM adverse effects among 11,636 participants in the AZD1222 vaccine trials is extremely high considering a worldwide incidence of 0.5/million COVID-19-associated ATM cases found in this report. The pathogenesis of ATM remains unknown, but it is conceivable that SARS-CoV-2 antigens –perhaps also present in the AZD1222 COVID-19 vaccine or its chimpanzee adenovirus adjuvant– may induce immune mechanisms leading to the myelitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166 · cited 3×
“Early reports of neurological complications of COVID-19 from China (2) and France (3) included no cases of ATM.”
BackgroundEndothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358 · cited 1×
“Stroke is common, probably reflecting the endoteliitis (62) and small-vessel brain lesions (4) causing brain hemorrhages, arterial and venous thromboses, and subarachnoid hemorrhage, as well as rare cases of acute hemorrhagic necrotizing encephalopathy (48, 61).”
BackgroundVoysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 2×
“IFN release can result in inflammation and immune system suppression (70).”
BackgroundNeurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674
Meinhardt, J., Radke, J., Dittmayer, C., Franz, J., Thomas, C., Mothes, R., Laue, M., Schneider, J., Brünink, S., Greuel, S., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00758-5 · Cited by 1,458
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
Matschke, J., Lütgehetmann, M., Hagel, C., Sperhake, J. P., Schröder, A. S., Edler, C., Mushumba, H., Fitzek, A., Allweiss, L., Dandri, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30308-2 · Cited by 1,300
Neuroinvasion of SARS-CoV-2 in human and mouse brain
Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A. V., Skriabine, S., Lu, P., Weizman, O.-E., Liu, F., Dai, Y., et al. (2020) · doi:10.1101/2020.06.25.169946 · Cited by 1,064
Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., & Spudich, S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2065 · Cited by 923
Neuropathological features of Covid-19
Solomon, I. H., Normandin, E., Bhattacharyya, S., Mukerji, S. S., Keller, K., Ali, A. S., Adams, G., Hornick, J. L., Padera, R. F., & Sabeti, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2019373 · Cited by 815
Microvascular injury in the brains of patients with Covid-19
Lee, M.-H., Perl, D. P., Nair, G., Li, W., Maric, D., Murray, H., Dodd, S. J., Koretsky, A. P., Watts, J. A., Cheung, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2033369 · Cited by 562 · cited 3×
“Neuropathological examination of fatal adult cases of COVID-19 (63–65) showed in addition to vascular lesions (4) low-grade localized encephalitis affecting brainstem respiratory and cardiovascular centers (63).”
BackgroundReichard, R. R., Kashani, K. B., Boire, N. A., Constantopoulos, E., Guo, Y., & Lucchinetti, C. F. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02166-2 · Cited by 479
Molecular Pathogenicity of Enteroviruses Causing Neurological Disease
Majer, A., McGreevy, A., & Booth, T. F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00540 · Cited by 50 · cited 1×
“Nonpolio enteroviruses, including EV-D68 and EV-A71, are the most frequent etiological agents (81).”
Background
Cited by
Neurological side effects of SARS‐CoV‐2 vaccinations
Finsterer, J. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13550 · Cited by 165
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
Frontera, J. A., Tamborska, A. A., Doheim, M. F., Garcia‐Azorin, D., Gezegen, H., Guekht, A., Yusof Khan, A. H. K., Santacatterina, M., Sejvar, J., Thakur, K. T., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26339 · Cited by 108
Metadata
- Authors
- Román, G. C., Gracia, F., Torres, A., Palacios, A., Gracia, K., & Harris, D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-26
- Volume
- 12
- Pages
- 653786-653786
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3160530878
- Cited by
- 237
- References
- 15
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.